drugset / Trial / NCT00125944

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

NCT00125944

Phase 3 Completed 300 enrolled MedImmune LLC
RandomizedParallel-groupDouble-blind

Summary

The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.

Timeline

Start
2005-07
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine

Indications